Glecaprevir
As of the edition of 20 October 2026, Glecaprevir is a small molecule: marketed, first approved in 2017 (EU); US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Mavyret
- First approved
- 26 July 2017 (EU)
- Approvals on record
- 10 in 5 regions
- Holder of the most recent approval
- AbbVie; 2 holders in all
- Registered trials
- 57, 5 stopped early
- Disease areas
- Digestive system; Infections; Urinary and reproductive; Pregnancy and women's health; Immune system; Mental health
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product21 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 21 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 4 | 1 | 1 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 7 | 6 | 1 | 0 |
| Phase 3 | 27 | 26 | 0 | 0 |
| Phase 4 | 11 | 4 | 2 | 4 |
| All trials | 57 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Applicant and Lead sponsor of trials | 2017 to now |